Global Blood Glucose Meters and Strips and Continuous Glucose Monitoring Market Size By Type (GDH-FAD, Other), By Application (Pet Hospital, Veterinary Station), By Region, And Segment Forecasts, 2023...

The Global Blood Glucose Meters and Strips and Continuous Glucose Monitoring (CGM) Market was valued at USD 14.2 billion in 2023 and is projected to surpass USD 25.6 billion by 2031, growing at a CAGR of 7.7% during the forecast period from 2023 to 2031. The market is witnessing robust growth driven by the global surge in diabetes prevalence, increasing health awareness, and a rising demand for real-time glucose monitoring solutions. Technological innovations in both blood glucose meters and CGMs are further fueling the market, offering improved accuracy, connectivity features, and user convenience. The shift toward minimally invasive or non-invasive monitoring methods is also reshaping patient adherence and long-term diabetes management.

Drivers:

Rising Prevalence of Diabetes Worldwide

The increasing incidence of Type 1 and Type 2 diabetes, particularly in low- and middle-income countries, is a key factor propelling the demand for both traditional and continuous glucose monitoring devices.

Advancements in Monitoring Technologies

Smart blood glucose meters integrated with Bluetooth, cloud connectivity, and AI-powered CGM systems have improved real-time tracking and analytics, enhancing patient outcomes and encouraging proactive disease management.

Increasing Health Awareness and Preventive Healthcare

Growing awareness about preventive health, early diagnosis, and diabetes-related complications is prompting consumers to invest in personal monitoring devices.

Restraints:

High Cost of Continuous Glucose Monitoring Devices

Despite their effectiveness, CGMs are often expensive, making them less accessible in developing regions and to patients without comprehensive insurance coverage.

Calibration and Accuracy Concerns

Some CGM devices require frequent calibration or may show discrepancies compared to lab-based results, which can affect patient trust and adoption.

Opportunity:

Integration with Mobile Health Platforms and Telemedicine

With the rise of telehealth and digital health platforms, the integration of glucose monitors with mobile apps is creating opportunities for remote diabetes management and real-time clinician support.

Untapped Potential in Emerging Markets

Countries in Asia-Pacific, Latin America, and Africa are witnessing rising diabetes rates, presenting significant market expansion opportunities with tailored, cost-effective devices.

Development of Non-Invasive Glucose Monitoring Solutions

Ongoing R&D in non-invasive glucose monitoring technologies, such as optical sensors and smartwatches, holds transformative potential for the market.

Market by System Type Insights:

In 2023, Blood Glucose Meters and Strips remained the dominant segment due to their affordability and widespread availability. However, the Continuous Glucose Monitoring (CGM) segment is expected to grow at the fastest rate during the forecast period, driven by increasing patient preference for continuous, real-time data and decreasing device costs.

Market by End-use Insights:

Hospitals and Clinics led the market in 2023, accounting for the largest revenue share owing to high patient turnover and the availability of advanced monitoring technologies. The Homecare segment is poised for rapid growth, supported by the global trend towards self-monitoring, remote care, and convenience.

Market by Regional Insights:

North America dominated the market in 2023, attributed to high healthcare expenditure, favorable reimbursement policies, and rapid technological adoption. The Asia-Pacific region is expected to exhibit the highest CAGR during the forecast period, fueled by growing diabetes prevalence, urbanization, and improving healthcare infrastructure in countries like India and China.

Competitive Scenario:

Leading players in the market include Abbott Laboratories, Dexcom, Inc., F. Hoffmann-La Roche Ltd, Medtronic plc, Ascensia Diabetes Care, LifeScan, Inc., Senseonics Holdings, Inc., Arkray, Inc., and Acon Laboratories, Inc. These companies are focusing on product innovation, strategic partnerships, and regulatory approvals to expand their market footprint. For instance:

Abbott expanded its FreeStyle Libre CGM product line in 2024 with enhanced Bluetooth capabilities and integration with digital health apps.

Dexcom launched a smaller, wearable CGM sensor in 2023 to improve user comfort and discretion.

Medtronic received FDA approval for a hybrid closed-loop insulin delivery system that integrates with CGMs, advancing personalized diabetes care.

Scope of Work – Global Blood Glucose Meters and Strips and Continuous Glucose Monitoring Market

Report Metric Details

Market Size (2023) USD 14.2 Billion

Projected Market Size (2031) USD 25.6 Billion

CAGR (2023–2031) 7.7%

Market Segments Blood Glucose Meters, Test Strips, CGM Systems

Growth Drivers Diabetes prevalence, Tech advancements, Self-monitoring trend

Opportunities Mobile integration, Non-invasive tech, Emerging market access

Key Market Developments:

March 2024: Abbott received CE mark approval for its latest FreeStyle Libre 4 system with enhanced accuracy and real-time alerts.

July 2023: Dexcom introduced a CGM subscription model to enhance affordability for long-term users.

October 2022: Senseonics launched the longest-lasting implantable CGM system, offering 180-day wear time.

FAQs:

What is the current market size of the Global Blood Glucose Meters and Strips and Continuous Glucose Monitoring Market?

The market was valued at USD 14.2 billion in 2023.

What is the major growth driver of the Global Blood Glucose Meters and Strips and Continuous Glucose Monitoring Market?

The rising global prevalence of diabetes and the demand for accurate self-monitoring solutions are key growth drivers.

Which is the largest region during the forecast period in the Global Blood Glucose Meters and Strips and Continuous Glucose Monitoring Market?

North America holds the largest market share, supported by strong healthcare infrastructure and early adoption of new technologies.

Which segment accounted for the largest market share in Global Blood Gl